company background image
SLN logo

Silence Therapeutics NasdaqGM:SLN Stock Report

Last Price

US$6.93

Market Cap

US$326.2m

7D

-54.5%

1Y

-40.0%

Updated

20 Nov, 2024

Data

Company Financials +

Silence Therapeutics plc

NasdaqGM:SLN Stock Report

Market Cap: US$326.2m

SLN Stock Overview

A biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. More details

SLN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Silence Therapeutics plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Silence Therapeutics
Historical stock prices
Current Share PriceUS$6.93
52 Week HighUS$27.72
52 Week LowUS$5.81
Beta1.29
11 Month Change-61.44%
3 Month Change-55.38%
1 Year Change-40.00%
33 Year Change-68.33%
5 Year Changen/a
Change since IPO-64.46%

Recent News & Updates

Some Shareholders Feeling Restless Over Silence Therapeutics plc's (NASDAQ:SLN) P/S Ratio

Oct 04
Some Shareholders Feeling Restless Over Silence Therapeutics plc's (NASDAQ:SLN) P/S Ratio

Silence Therapeutics plc (NASDAQ:SLN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Aug 18
Silence Therapeutics plc (NASDAQ:SLN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Recent updates

Some Shareholders Feeling Restless Over Silence Therapeutics plc's (NASDAQ:SLN) P/S Ratio

Oct 04
Some Shareholders Feeling Restless Over Silence Therapeutics plc's (NASDAQ:SLN) P/S Ratio

Silence Therapeutics plc (NASDAQ:SLN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Aug 18
Silence Therapeutics plc (NASDAQ:SLN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Silence Therapeutics plc's (NASDAQ:SLN) Shareholders Might Be Looking For Exit

Jun 17
Silence Therapeutics plc's (NASDAQ:SLN) Shareholders Might Be Looking For Exit

Here's Why We're Not Too Worried About Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation

May 21
Here's Why We're Not Too Worried About Silence Therapeutics' (NASDAQ:SLN) Cash Burn Situation

Need To Know: Analysts Are Much More Bullish On Silence Therapeutics plc (NASDAQ:SLN) Revenues

Feb 07
Need To Know: Analysts Are Much More Bullish On Silence Therapeutics plc (NASDAQ:SLN) Revenues

Subdued Growth No Barrier To Silence Therapeutics plc (NASDAQ:SLN) With Shares Advancing 65%

Nov 27
Subdued Growth No Barrier To Silence Therapeutics plc (NASDAQ:SLN) With Shares Advancing 65%

Silence Therapeutics wins FDA’s fast track status for blood cancer therapy

Sep 08

Silence Therapeutics prices 5.95M ADSs at $9.50/share

Aug 12

New finance chief for Silence Therapeutics

Jan 06

Shareholder Returns

SLNUS BiotechsUS Market
7D-54.5%-6.5%-1.0%
1Y-40.0%14.6%30.3%

Return vs Industry: SLN underperformed the US Biotechs industry which returned 14.1% over the past year.

Return vs Market: SLN underperformed the US Market which returned 30.4% over the past year.

Price Volatility

Is SLN's price volatile compared to industry and market?
SLN volatility
SLN Average Weekly Movement12.8%
Biotechs Industry Average Movement9.7%
Market Average Movement6.2%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.1%

Stable Share Price: SLN's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: SLN's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1994109Craig Toomanwww.silence-therapeutics.com

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company’s mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera.

Silence Therapeutics plc Fundamentals Summary

How do Silence Therapeutics's earnings and revenue compare to its market cap?
SLN fundamental statistics
Market capUS$326.18m
Earnings (TTM)-US$74.44m
Revenue (TTM)US$20.54m

15.8x

P/S Ratio

-4.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SLN income statement (TTM)
RevenueUK£16.25m
Cost of RevenueUK£8.97m
Gross ProfitUK£7.27m
Other ExpensesUK£66.14m
Earnings-UK£58.86m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.26
Gross Margin44.78%
Net Profit Margin-362.34%
Debt/Equity Ratio0%

How did SLN perform over the long term?

See historical performance and comparison